grant
Mapping amyloid, tau, and neurodegeneration markers with neuropsychiatric phenotypes and genotypes in Alzheimer's disease continuum using machine learning
Organization WASHINGTON UNIVERSITYLocation SAINT LOUIS, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY202565 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years oldAD dementiaAD pathologyAI algorithmAI basedAI based methodAI based modelAI modelAI systemAddressAffectAged 65 and OverAgingAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's disease pathologyAlzheimer's disease patientAlzheimer's pathologyAlzheimer's patientAlzheimers DementiaAmentiaAmericanAmyloidAmyloid (Aβ) plaquesAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid PlaquesAmyloid Protein A4Amyloid SubstanceAmyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinArtificial IntelligenceAβBaltimoreBiological MarkersBlood VesselsBrainBrain Nervous SystemBrain regionCausalityCharacteristicsClinicalCognitiveComplexComputer AssistedComputer ReasoningDataDegenerative Neurologic DisordersDementiaDiagnosisDimensionsDiseaseDisorderElderly depressionEncephalonEquipment and supply inventoriesEtiologyExhibitsFutureGeneticGenetic PredispositionGenetic Predisposition to DiseaseGenetic RiskGenetic SusceptibilityGenetic predisposing factorGenetic propensityGenotypeGoalsHeterogeneityImageImaging ProceduresImaging TechnicsImaging TechniquesIndividualInherited PredispositionInherited SusceptibilityInventoryLinkLongitudinal StudiesMR ImagingMR TomographyMRIMRI biomarkerMRI markerMRIsMT-bound tauMachine IntelligenceMachine LearningMagnetic Resonance ImagingMapsMeasuresMedicalMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMental DepressionMethodologyMethodsModalityMultimodal ImagingNMR ImagingNMR TomographyNerve DegenerationNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeuranatomiesNeuranatomyNeuritic PlaquesNeuroanatomiesNeuroanatomyNeurobiologyNeurodegenerative DiseasesNeurodegenerative DisordersNeurofibrillary TanglesNeurologic Degenerative ConditionsNeuron DegenerationNuclear Magnetic Resonance ImagingOutcomePETPET ScanPET imagingPETSCANPETTPatientsPatternPattern RecognitionPhenotypePositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrecision therapeuticsPrevalencePrimary Senile Degenerative DementiaProcessPublic HealthQuestionnairesRad.-PETReproducibilityResearchRiskSamplingSenile PlaquesSeveritiesSubgroupTechniquesTestingTherapeuticTimeUniversitiesWashingtonZeugmatographya beta peptideabetaabove age 65after age 65age 65 and greaterage 65 and olderage 65 or olderageage of 65 years onwardaged 65 and greateraged 65+aged ≥65amyloid betaamyloid beta plaqueamyloid-b plaqueamyloid-b proteinanalytical methodartificial intelligence algorithmartificial intelligence basedartificial intelligence methodartificial intelligence modelartificial intelligence-based modelaβ plaquesbeta amyloid fibrilbio-markersbiologic markerbiomarkercase controlcase-controlledcausationco-morbidco-morbiditycohortcomorbiditycomputer aidedcored plaquedata harmonizationdata modalitiesdata resourcedeep learning based neural networkdeep learning neural networkdeep neural netdeep neural networkdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdepressiondesigndesigningdiagnostic abilitydiagnostic capabilitydiagnostic powerdiagnostic utilitydiagnostic valuediffuse plaquedisease causationdisease heterogeneitygenetic etiologygenetic mechanism of diseasegenetic risk factorgenetic vulnerabilitygenetically predisposedgeriatric depressionharmonized datahuman old age (65+)image-based methodimagingimaging biomarkerimaging markerimaging methodimaging modalityimaging-based biological markerimaging-based biomarkerimaging-based markerimproved outcomein vivoindexinginherited factorinnovateinnovationinnovativelate life depressionlong-term studylongitudinal outcome studiesmachine based learningmachine learning based methodmachine learning based prediction modelmachine learning based predictive modelmachine learning methodmachine learning methodologiesmachine learning predictionmachine learning prediction modelmagnetic resonance imaging biomarkermagnetic resonance imaging markermethod developmentmicrotubule bound taumicrotubule-bound taumild cognitive disordermild cognitive impairmentmulti-modal imagingmulti-modalitymulti-modality imagingmultimodalitymultimodality imagingneural degenerationneural imagingneuro-imagingneurobiologicalneurodegenerationneurodegenerativeneurodegenerative illnessneurofibrillary degenerationneurofibrillary lesionneurofibrillary pathologyneuroimagingneurological degenerationneurological imagingneuronal degenerationneuropsychiatricneuropsychiatric symptomneuropsychiatrynovelover 65 yearspatient living with Alzheimer's diseasepatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographyprecision medicineprecision therapiesprecision treatmentprecision-based medicineprimary degenerative dementiaprognosticpublic health relevancesecondary analysissenile dementia of the Alzheimer typesoluble amyloid precursor proteinsupervised learningsupervised machine learningtangletautau Proteinstau factortooltreatment effectuptakevascularvascular risk factorτ Proteins≥65 years
Description preview
Project Abstract / Summary
Alzheimer’s disease (AD) is the leading cause of dementia and has significant medical and public health
concerns. Despite extensive efforts, the exact relationships between in-vivo amyloid-beta (A), tau (T), and
neurodegeneration (N), neuropsychiatric symptoms (NPS), vascular risk factors, and genetic risks for NPS in
AD…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click